Taysha Gene Therapies Inc...

NASDAQ: TSHA · Real-Time Price · USD
2.79
0.01 (0.36%)
At close: Jun 04, 2025, 3:59 PM
2.87
2.87%
After-hours: Jun 04, 2025, 07:58 PM EDT

Taysha Gene Therapies Statistics

Share Statistics

Taysha Gene Therapies has 214.66M shares outstanding. The number of shares has increased by 1.8% in one year.

Shares Outstanding 214.66M
Shares Change (YoY) 1.8%
Shares Change (QoQ) 0.03%
Owned by Institutions (%) 62.39%
Shares Floating n/a
Failed to Deliver (FTD) Shares 10,463
FTD / Avg. Volume 0.33%

Short Selling Information

The latest short interest is 26.24M, so 12.22% of the outstanding shares have been sold short.

Short Interest 26.24M
Short % of Shares Out 12.22%
Short % of Float 14.11%
Short Ratio (days to cover) 5.7

Valuation Ratios

The PE ratio is -4.85 and the forward PE ratio is -7.33. Taysha Gene Therapies's PEG ratio is 0.08.

PE Ratio -4.85
Forward PE -7.33
PS Ratio 51.93
Forward PS 1.6
PB Ratio 6.05
P/FCF Ratio -5.3
PEG Ratio 0.08
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Taysha Gene Therapies.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.88.

Current Ratio 5.42
Quick Ratio 5.42
Debt / Equity 0.88
Debt / EBITDA -0.72
Debt / FCF -0.77
Interest Coverage -896.66

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $114,150.68
Profits Per Employee $-1,223,260.27
Employee Count 73
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -24.18% in the last 52 weeks. The beta is 0.88, so Taysha Gene Therapies's price volatility has been higher than the market average.

Beta 0.88
52-Week Price Change -24.18%
50-Day Moving Average 1.98
200-Day Moving Average 1.95
Relative Strength Index (RSI) 61.84
Average Volume (20 Days) 3,205,163

Income Statement

In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.3M in profits. Earnings per share was -0.36.

Revenue 8.33M
Gross Profit 7.09M
Operating Income -91.46M
Net Income -89.3M
EBITDA -87.95M
EBIT -89.2M
Earnings Per Share (EPS) -0.36
Full Income Statement

Balance Sheet

The company has 139.04M in cash and 63.18M in debt, giving a net cash position of 75.86M.

Cash & Cash Equivalents 139.04M
Total Debt 63.18M
Net Cash 75.86M
Retained Earnings -602.3M
Total Assets 138.36M
Working Capital 98.15M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -81.22M and capital expenditures -374K, giving a free cash flow of -81.6M.

Operating Cash Flow -81.22M
Capital Expenditures -374K
Free Cash Flow -81.6M
FCF Per Share -0.33
Full Cash Flow Statement

Margins

Gross margin is 85.06%, with operating and profit margins of -1097.55% and -1071.62%.

Gross Margin 85.06%
Operating Margin -1097.55%
Pretax Margin -1071.62%
Profit Margin -1071.62%
EBITDA Margin -1055.45%
EBIT Margin -1097.55%
FCF Margin -979.23%

Dividends & Yields

TSHA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for TSHA is $7, which is 150.9% higher than the current price. The consensus rating is "Buy".

Price Target $7
Price Target Difference 150.9%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score -3.22
Piotroski F-Score 3